RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion “When it comes to immunotherapy, one of the most important findings that we’ve made in the last several years is an understanding of the targets of the immune system on the cancer,” Rosenberg said. “The fact that we can now, today, identify T cells that recognize a cancer in 70% to 80% of all patients with metastatic cancer holds substantial optimism for the ability to take advantage of that in developing new treatments. One of the advantages of cell therapy — it’s a living drug. When we inject those lymphocytes that can recognize the cancer, they expand thousands-fold in the first week or two after they are injected." - [ like has been demonstrated with ONCY's platform biologic pelareorep in the treatment of multiple cancers ]
“I see immunotherapy playing a very important part of the future of cancer treatment in addition to the standard treatments,” he added. “I’m a surgeon, and probably 80% of people who can be cured of cancer today are cured by surgery. I don’t expect the current methods to be completely replaced, but I do see immunotherapy adding to treatment either in conjunction with other modalities or as a standalone treatment.”